| Dr David Ira Waddell, MD | |
|
1050 River Oaks Dr, Suite 200, Flowood, MS 39232-9564 | |
| (601) 420-0134 | |
| (601) 420-0547 |
| Full Name | Dr David Ira Waddell |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 31 Years |
| Location | 1050 River Oaks Dr, Flowood, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609964683 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 13919 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Dominic-jackson Memorial Hospital | Jackson, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Womens Health Associates Pllc | 3678476983 | 6 |
News Archive
Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.
A state-mandated policy restricting opioid prescriptions along with increased public awareness and education about the opioid epidemic preceded drastic reductions in opioid prescribing and use for surgical patients at the University of Vermont Medical Center without impacting patient satisfaction with their postoperative pain management, according to findings presented at the American College of Surgeons Clinical Congress 2019.
Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contraceptive efficacy for birth control pills would not be altered by SYM-1219 administration.
New recommendations from the American Thyroid Association on outpatient radioiodine treatment aim to minimize unintended radiation exposure and maximize the safety of patients, their families, and the public.
Purchasers of pharmaceutical drugs including consumers and health plans will soon enjoy a rollback of benchmark prices of some of the most common prescription medications after a Federal Appeals Court last week affirmed the approval of a settlement with two leading drug-pricing publishers, First DataBank, Inc. and Medi-Span, a division of Wolters Kluwer Health, Inc.
› Verified 4 days ago
| Entity Name | Womens Health Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316036353 PECOS PAC ID: 3678476983 Enrollment ID: O20040202000456 |
News Archive
Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.
A state-mandated policy restricting opioid prescriptions along with increased public awareness and education about the opioid epidemic preceded drastic reductions in opioid prescribing and use for surgical patients at the University of Vermont Medical Center without impacting patient satisfaction with their postoperative pain management, according to findings presented at the American College of Surgeons Clinical Congress 2019.
Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contraceptive efficacy for birth control pills would not be altered by SYM-1219 administration.
New recommendations from the American Thyroid Association on outpatient radioiodine treatment aim to minimize unintended radiation exposure and maximize the safety of patients, their families, and the public.
Purchasers of pharmaceutical drugs including consumers and health plans will soon enjoy a rollback of benchmark prices of some of the most common prescription medications after a Federal Appeals Court last week affirmed the approval of a settlement with two leading drug-pricing publishers, First DataBank, Inc. and Medi-Span, a division of Wolters Kluwer Health, Inc.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Ira Waddell, MD 1050 River Oaks Dr, Suite 200, Flowood, MS 39232-9564 Ph: (601) 420-0134 | Dr David Ira Waddell, MD 1050 River Oaks Dr, Suite 200, Flowood, MS 39232-9564 Ph: (601) 420-0134 |
News Archive
Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.
A state-mandated policy restricting opioid prescriptions along with increased public awareness and education about the opioid epidemic preceded drastic reductions in opioid prescribing and use for surgical patients at the University of Vermont Medical Center without impacting patient satisfaction with their postoperative pain management, according to findings presented at the American College of Surgeons Clinical Congress 2019.
Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contraceptive efficacy for birth control pills would not be altered by SYM-1219 administration.
New recommendations from the American Thyroid Association on outpatient radioiodine treatment aim to minimize unintended radiation exposure and maximize the safety of patients, their families, and the public.
Purchasers of pharmaceutical drugs including consumers and health plans will soon enjoy a rollback of benchmark prices of some of the most common prescription medications after a Federal Appeals Court last week affirmed the approval of a settlement with two leading drug-pricing publishers, First DataBank, Inc. and Medi-Span, a division of Wolters Kluwer Health, Inc.
› Verified 4 days ago
Dr. Charles Shannon Carroll, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 291 E Layfair Dr, Flowood, MS 39232 Phone: 601-936-9190 Fax: 601-932-6714 | |
Dr. Joel G Payne Jr., MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 291 E Layfair Dr, Flowood, MS 39232 Phone: 601-936-9190 Fax: 601-932-6714 | |
Mrs. Kay Elizabeth Midler, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1050 River Oaks Drive, Suite 200, Flowood, MS 39232 Phone: 601-200-8201 Fax: 601-987-0019 | |
Dr. John W Cook, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 291 E Layfair Dr, Flowood, MS 39232 Phone: 601-936-9190 Fax: 601-932-6714 | |
Dr. Shimeka Lanette Banks, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1307-b Airport Road North, Flowood, MS 39232 Phone: 601-825-7280 | |
Dr. Lindsey Miller Turner, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1020 River Oaks Dr Ste 320, Flowood, MS 39232 Phone: 601-936-1400 Fax: 601-936-1416 | |
Dr. Natasha N Hardeman, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2506 Lakeland Dr Ste 600, Flowood, MS 39232 Phone: 601-939-1600 Fax: 601-939-1606 |